|
Co-payment
|
-
|
Atella et al. [76] (IT, NS, CD, R); Gibson et al. [191] (US, OS, CD, R); Poirier et al. [77] (CA, NS, TD, NR)
|
|
Co-payment
|
0
|
Poirier et al. [77] (CA, NS, TD, NR)
|
|
Multi-tier formulary (vs. 1- or 2-tiers)
|
-
|
Landsman et al. [65] (US, NS, TD, R); Shrank et al. [79] (US, OS, CD, R); Taira et al. [80] (US, OS, CD, R)
|
|
Co-insurance
|
-
|
Reuveni et al. [192] (IS, OS, CD, R)
|
|
Mixed system
|
-
|
Ellis et al. [193] (US, OS, CD, R); Goldman et al. [194] (US, OS, CD, R); Mojtabai and Olfson [195] (US, OS, CD, R); Piette et al. [196] (US, OS, CD, R)
|
|
Change from
| | |
|
co-payment to deductible and co-insurance
|
0
|
Pilote et al. [30] (CA, NS, CD, R)
|
|
Has co-insurance (vs. has co-payment)
|
-
|
Dor and Encinosa [78] (US, OS, CD, R)
|
|
Insurance coverage
| | |
|
Primary (vs. none)
|
+
|
Kennedy and Erb [197] (US, OS, CD, NR); Piette et al. [196] (US, OS, CD, R); Thomas et al. [144] (US, OS, CD, R)
|
|
Primary public (vs. private)
|
-
|
Dodrill et al. [198] (US, OS, CD, NR)
|
|
Supplementary (vs. none)
|
+
|
Col et al. [199] (US, OS, CD, R); Safran et al. [200] (US, OS, CD, R); Schoen et al. [74] (US, NS, CD, NR); Steinman et al. [201] (US, OS, CD, R)
|
|
Prescription limit
|
-
|
Cox et al. [35] (US, OS, CD, R); Schulz et al. [81] (US, NS, CD, NR)
|
